Chronic Lymphocytic Leukemia Industry Overview
|Study Period:||2018 - 2028|
|Fastest Growing Market:||Asia Pacific|
|Largest Market:||North America|
|CAGR:||> 6.01 %|
*Disclaimer: Major Players sorted in no particular order
Need a report that reflects how COVID-19 has impacted this market and its growth?
Chronic Lymphocytic Leukemia Market Analysis
The global Chronic Lymphocytic Leukemia (CLL) Market is expected to register a CAGR of 6.01% over the forecast period (2022-2027).
The Covid-19 pandemic has had a significant impact on the market studied. Cancer treatments such as chemotherapy and immune suppressants typically damage the patient's immune system. This weakened immune system of the target population is expected to create a risk of Covid-19 infection. Various research has been conducted to find the impact of Covid 19 on the CLL patients. According to the research article “Covid-19 in patients with chronic lymphocytic leukemia: clinical outcome and B- and T-cell immunity during 13 months in consecutive patients” published in September 2021, due to immunodeficiency brought on by the illness and its treatment, patients with chronic lymphocytic leukemia (CLL) are more vulnerable to serious infections. And Covid-19 remained to have a high admission rate even among consecutive and young early-stage CLL patients. This is expected to have created a demand for the availability of treatment for CLL drugs and therapies which is further expected to bolster the studied market growth. Therefore, the pandemic is expected to significantly impact the studied market growth.
Factors such as the rise in the global prevalence of chronic lymphocytic leukemia coupled with the increasing geriatric population and huge product pipeline along with growing research activities are fuelling the market growth.
The world is aging with the increasing geriatric population across the countries and creating various disease burdens. The data updated by World Health Organization (WHO) in October 2021 shows that 1 in 6 individuals will be 60 or older by 2030 globally. By this time, there will be 1.4 billion people over the age of 60, up from 1 billion in 2020. The number of persons in the globe who are 60 years or older will double by 2050. (2.1 billion). In addition, according to the article “Chronic lymphocytic leukemia: 2022 update on diagnostic and therapeutic procedures” published in October 2021, the age-adjusted incidence of chronic lymphocytic leukemia (CLL) is 4.9 per 100 000 inhabitants per year making CLL one of the most common types of leukemia. As per the source above, the median age at diagnosis is 70 years and only 9.1% of patients with CLL are younger than 45 years. Thus, the increasing geriatric population coupled with the burden of CLL among the target population is expected to create opportunities for CLL treatment. Thereby, driving the market growth over the analysis period.
Furthermore, the recent development in CLL treatment is increasing recently. For instance, in November 2021, as per TG Therapeutics, Inc.’s press release, the Food and Drug Administration (FDA) planned to host a meeting of the Oncologic Drugs Advisory Committee (ODAC) in connection with its review of the pending Biologics License Application (BLA)/supplemental New Drug Application (sNDA) for the combination of ublituximab and UKONIQ (umbralisib) (combination referred to as U2) for the treatment of adult patients with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). And in December 2021 the company presented favorable outcomes for patients treated with U2 with co-morbidities or concomitant medications and a retrospective analysis of the Unity-CLL Phase 3 Trial at the American Society of Hematology (ASH) Annual Meeting. Thus, such advances in the market are anticipated to boost the demand for the availability of the CLL treatment, this is further driving the market growth.
Thus, the studied market is expanding, with the increase in research activities, and is anticipated to witness growth over the forecast period. However, the higher cost of the patented drugs and therapy and the side effects associated with chemotherapy are expected to restrain the growth of the market.
Chronic Lymphocytic Leukemia Industry Segments
As per the scope of the report, chronic lymphocytic leukemia (CLL) is the common type of leukemia predominantly affecting the population of age 50 and over globally. CLL is characterized by the abnormal development of malignant B lymphocytes in the bone marrow which travels through the peripheral blood. The Chronic Lymphocytic Leukemia Market is segmented by Route of Administration (Oral, Parenteral and Others), Treatment (Chemotherapy, Immunotherapy and Others), Distribution Channel (Hospitals, Specialty Clinics and Others), and Geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America). The report also covers the estimated market sizes and trends for 17 countries across major regions globally. The report offers the value (in USD million) for the above segments.
|By Route of Administration|
|By Distribution Channel|
Chronic Lymphocytic Leukemia Market Trends
This section covers the major market trends shaping the Chronic Lymphocytic Leukemia Market according to our research experts:
Parenteral Route of Administration Segment is Expected to Witness Growth Over the Forecast Period
The parenteral route of administration segment is expected to witness growth in recent years and is expected to do so over the forecast period. This dominance is due to their rapid absorption and onset of action along with their availability in various routes such as intravenous, subcutaneous, intrathecal, or intramuscular routes according to the need of the patient.
The data updated by the National Library of Medicine for “Medication Routes of Administration” in February 2022, the parenteral route of administration can be done in three different ways such as intravenous injections, intramuscular and subcutaneous injections, among which Intravenous injection is the common parental route of administration due to its benefit of bypassing the first-pass metabolism by the liver. In addition, as per the Ascendia Pharmaceuticals data updated in 2022 stated that the quickest and second-most popular method of drug delivery is parenteral formulation development for medications given by injection or infusion. Additionally, as per the source mentioned above, a major benefit of parenteral administration is that it can provide a rapid onset of action and rapid absorption of the drug. Thus, such benefits and advantages of the parenteral route of administration the segment is anticipated to grow over the forecast period.
Furthermore, the availability of the dugs for parenteral administration for the treatment of chronic lymphocytic leukemia (CLL) is one of the factors affecting segment growth. As per data medically reviewed by Drugs.com in April 2022, Bendamustine Hydrochloride Injection is indicated for the treatment of patients with CLL with a recommended dose of 100 mg/m2 administered intravenously over 30 minutes on Days 1 and 2 of a 28-day cycle, up to 6 cycles. Thus, such instances are predicted to bolster the market growth in the future.
Therefore, owing to the aforesaid factors the studied segment is anticipated to show growth over the forecast period.
To understand key trends, Download Sample Report
North America is expected to Dominate the Market During the Forecast Period As Well
North America is anticipated to witness growth over the forecast period and dominate the market. Among other countries in the region, the United States is leading the market due to high healthcare expenditure, research and developments activites, and a rising prevalence of Chronic Lymphocytic Leukemia (CLL). Additionally, the rising geriatric population across the United States is the primary driver for the United States CLL market.
The data updated by the American Cancer Society in 2022, nearly 60,650 new cases of leukemia (all kinds) are estimated to be diagnosed in 2022, among which chronic lymphocytic leukemia (CLL) accounts for approximately 20,160 new cases. Additionally, as per the source mentioned above, about 1/4th of newly diagnosed cases of leukemia is CLL. The lifetime chance of developing CLL is approximately 1 in 175 (0.57%) for the average person. Most people with CLL are older individuals typically of age 70 years old when they receive a diagnosis. In addition, the data updated in February 2022 by HealthyPeople.gov, a Federal z website managed by the United States Department of Health and Human Services shows that the population in the United States is aging unprecedently and the population aged 65 or older is projected to reach 23.5% (98 million) by 2060 in the country. Thus, with the increasing geriatric population in the country, the risk of CLL is also rising. This is expected to generan te demand for the availability of drugs and therapy for the disease for treatment. Hence, the studied market is anticipated to grow over the forecast period.
Moreover, the increasing research and development of various treatment options in the country are anticipated to drive market growth over the forecast period. For instance, in September 2021, Triplet therapy developed by researchers at the Dana-Farber Cancer Institute showed promise in a phase 2 study in chronic lymphocytic leukemia. As per the trial results, 86% of the trial participants demonstrated a significant response over the course of the two-year study, and no minimal residual disease (MRD) could be detected in these patients’ bone marrow using sensitive cellular tests which is a key predictor of survival without progression.
Therefore, owing to the factors mentioned above, North America is predicted to witness growth over the forecast period.
To understand geography trends, Download Sample Report
Chronic Lymphocytic Leukemia Market Competitor Analysis
The Chronic lymphocytic leukemia market is moderately competitive and consists of several major players. Few of the key players are developing the biosimilars to the existing chemotherapies while others are launching the generic products trending in the market. Few key players are entering into partnerships to develop and increase their market position globally. Some of the companies which are currently dominating the market are F. Hoffmann-La Roche Ltd, AstraZeneca plc, Verastem Inc, Novartis AG, and AbbVie Inc., among others.
Chronic Lymphocytic Leukemia Market Top Players
F. Hoffmann-La Roche Ltd
Secura Bio, Inc
*Disclaimer: Major Players sorted in no particular order
Chronic Lymphocytic Leukemia Market Recent Developments
- In August 2022, following positive results of clinical trials, the Food and Drug Administration approved a tablet version of a drug called Calquence for the treatment of chronic lymphocytic leukemia (CLL), small lymphocytic leukemia (SLL), and previously treated relapsed or refractory mantle cell lymphoma (MCL) developed by AstraZeneca.
- In February 2022, The Food and Drug Administration accepted the review of a supplemental new drug application (sNDA) for zanubrutinib (Brukinsa) for the treatment of adult patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) and the drug is developed by BeiGene.
Chronic Lymphocytic Leukemia Market Report - Table of Contents
1.1 Study Assumptions and Market Definition
1.2 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Rise in Global Prevalence of Chronic Lymphocytic Leukemia Coupled With the Increasing Geriatric Population
4.2.2 Huge Product Pipeline along with Growing Research Activities
4.3 Market Restraints
4.3.1 Higher Cost of the Patented Drugs and Therapies
4.3.2 Side Effects Associated with Chemotherapy
4.4 Porter's Five Force Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5. MARKET SEGMENTATION (Market Size by Value - USD million)
5.1 By Route of Administration
5.2 By Treatment
5.3 By Distribution Channel
5.3.2 Speciality Clinics
5.4.1 North America
188.8.131.52 United states
184.108.40.206 United Kingdom
220.127.116.11 Rest of Europe
18.104.22.168 South Korea
22.214.171.124 Rest of Asia-Pacific
5.4.4 Middle East and Africa
126.96.36.199 South Africa
188.8.131.52 Rest of Middle East and Africa
5.4.5 South America
184.108.40.206 Rest of South America
6. COMPETITIVE LANDSCAPE
*List Not Exhaustive
6.1 Company Profiles
6.1.1 F. Hoffmann-La Roche Ltd
6.1.3 Secura Bio, Inc
6.1.4 Novartis AG
6.1.5 AbbVie, Inc.
6.1.6 Gilead Sciences, Inc.
6.1.7 BeiGene, Inc.
6.1.8 Sanofi (Genzyme Corporation)
6.1.9 Ziopharm Oncology Inc
6.1.10 Ono pharmaceuticals Co Ltd
6.1.11 Teva Pharmaceutical Industries
7. MARKET OPPORTUNITIES AND FUTURE TRENDS
Chronic Lymphocytic Leukemia Market Research FAQs
What is the study period of this market?
The Global Chronic Lymphocytic Leukemia Market is studied from 2018 - 2028.
What is the growth rate of Global Chronic Lymphocytic Leukemia Market?
The Global Chronic Lymphocytic Leukemia Market is growing at a CAGR of >6.01% over the next 5 years.
Which region has highest growth rate in Global Chronic Lymphocytic Leukemia Market?
Asia Pacific is growing at the highest CAGR over 2018 - 2028.
Which region has largest share in Global Chronic Lymphocytic Leukemia Market?
North America holds highest share in 2021.
Who are the key players in Global Chronic Lymphocytic Leukemia Market?
AbbVie Inc, F. Hoffmann-La Roche Ltd, Novartis AG, AstraZeneca, Secura Bio, Inc are the major companies operating in Global Chronic Lymphocytic Leukemia Market.
Global Chronic Lymphocytic Leukemia Industry Reports
In-depth industry statistics and market share insights of the Global Chronic Lymphocytic Leukemia sector for 2020, 2021, and 2022. The Global Chronic Lymphocytic Leukemia research report provides a comprehensive outlook of the market size and an industry growth forecast for 2023 to 2028. Available to download is a free sample file of the Global Chronic Lymphocytic Leukemia report PDF.